Skip to main content
Equibles
CDNA logo

CDNA · CareDx, Inc.

Track CDNA — free

Use CDNA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CDNA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$77.88 -1.93 (-2.42%) At close · Nov 13
Russell 2000 member Rebalance outlook locked
Market Cap
$4.09B
Shares
52.54M
Volume · Nov 13 716.98K Avg daily vol (3M) 1.32M

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$77.88 Open$78.51 Day$76.66–80.00 52W close$15.51–88.47 Avg vol 30d1.4M Short int7.2M · 13.7% of shares · 5.3d Short vol42% Last earningsOct 29, 2026 DataJan 2020–Nov 2026 Filing10-Q · Oct 29

Up next

Next earnings call
Feb 23, 2027 Est · unconfirmed · in 14 wks
Q2 2026 earnings call transcript
call held Jul 30, 2026
Play latest call

Latest documents

2026
Oct 29
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Quarterly report for FY2026 Q3

CareDx reported $139 million revenue and $19 million net income for the three months ended September 30, 2026. It sold its lab products business to Eurobio for $171.7 million and acquired Naveris for $203.3 million.

Revenue $139.36M ▲ 39.3% Net income $19.29M ▲ 1051.8% Diluted EPS $0.35 ▲ 1066.7%
Read from the MD&A section
Oct 29
Current report 8-K
Financial results, Regulation FD disclosure

CareDx reported third-quarter revenue of $139 million, up 39% year-over-year, and Adjusted EBITDA of $30 million. It raised 2026 revenue guidance to $520 million to $530 million and Adjusted EBITDA guidance to $90 million to $100 million.

Jul 30
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $131.95M ▲ 52.2% Net income $110.64M Diluted EPS $2.07
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$497.40M
Trailing 12 months
Net income (TTM)
$128.63M
Trailing 12 months
Revenue growth YoY
+39.3%
Year over year
Operating margin
23.4%
Trailing 12 months
P / E (TTM)
32.6
Trailing earnings · reciprocal yield 3.1%
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$250.48M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+2.3%
Year over year · more shares
Price change (1Y)
+390.7%
Trailing year
Short interest
13.7%
Latest settlement · 5.3 days to cover
View all 125 metrics

Quarterly results

Revenue Net income Net loss
▲32% $86.58M $87.70M '24 Q4* ▲17.5% $84.69M −$10.35M '25 Q1 ▼6.1% $86.68M −$8.57M '25 Q2 ▲20.7% $100.06M $1.68M '25 Q3 ▲25.2% $108.39M −$4.11M '25 Q4* ▲39% $117.70M $2.81M '26 Q1 ▲52.2% $131.95M $110.64M '26 Q2 LATEST ▲39.3% $139.36M $19.29M '26 Q3

* Q4 derived as the full year minus Q1 to Q3.

AI Brief

Q2 FY26 earnings call · Jul 30, 2026
Q2 FY26

TL;DR. CareDx reported 52% Q2 revenue growth to $132 million and raised 2026 revenue guidance to $490–$500 million and adjusted EBITDA guidance to $66–$78 million, driven by Testing Services growth, the closing of the Lab Products divestiture and Naveris (NAVDX) acquisition, and finalized Medicare coverage for AlloSure and AlloMap.

Bullish
  • + 2026 revenue guidance raised to $490–$500 million and adjusted EBITDA guidance raised to $66–$78 million.
  • + CMS finalized Medicare coverage policy for AlloSure and AlloMap, with a pathway for future HistoMap coverage.
Bearish
  • − Non-GAAP gross margin guidance of 71%–73% is below the 74% reported in Q2.
  • − Specialty oncology ASP is guided at only $770–$795 per test in Q3/Q4, well below the $1,455–$1,465 transplant ASP.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Neutral Fundamentals Excellent Quant / Vol Very High
Market backdrop VIX 19.3 · elevated Equity put/call 0.63
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +112%
above
Price vs 50-day avg +17%
above
RSI (14) 55
neutral
MACD trend Negative
52-week position 85%
near high
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +22%
trailing
6-month return +262%
trailing
YTD return +313%
this year
Relative strength +261%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $66 › 200d $37 — 50d above 200d
Institutional flow Accumulating
240 of 229 funds reported for Sep 30 · net +704.1K sh shares · +80 new
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
13.68% of shares out · ▲ +7.0% MoM · 5.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
229 holders — near 3-yr high, broad support
Squeeze score 78
high risk · 0–100
Fundamentals
Excellent
Revenue growth +19%
Y/Y
Gross margin 169%
expanding
EPS growth −143%
Y/Y
Free cash flow $40.0M
Valuation P/E 32.6
below peers
Buyback $100.0M
authorized
Balance sheet $65.4M
net cash
Quant / Vol
risk profile
Very High
Volatility 75%
annualized · 1-yr
Max drawdown −24%
past year
ATR 6.7%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 5 of last 5
Latest guidance · from the 8-K filed Oct 29, 2026
full year 2026
Revenue Raised $520M – $530M
Jul 30, 2026 $490M – $500M changed to Oct 29, 2026 $520M – $530M
prior FY $379.81M midpoint +38.2% Y/Y
full-year 2026
Adjusted EBITDA Non-GAAP Raised $90M – $100M
Jul 30, 2026 $66M – $78M changed to Oct 29, 2026 $90M – $100M
Previous outlook earlier release · from the Earnings Call filed Jul 30, 2026

Still-open targets the latest release did not restate under the same label.

Non-GAAP operating expenses · 2026 $293M – $297M
Non-GAAP gross margin · 2026 71% – 73%
Guided vs delivered · last 5 settled
Revenue full year 2025
guided $372M – $376M
$379.81M Beat +1.6%
Full year 2024 revenue full year 2024
guided $320M – $328M
$333.79M Beat +3.0%
Revenue full year 2023
guided $274M – $278M
$280.32M Beat +1.6%
Revenue full year 2022
guided $320M – $325M
$321.79M In line

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy
1 · 3 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+112% Bullish
Price vs 50-day avg
+17% Bullish
RSI (14)
55 Neutral
MACD trend
Negative Bearish
52-week position
85% Bullish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $66 › 200d $37 — 50d above 200d
Institutional flow Accumulating
240 of 229 funds reported for Sep 30 · net +704.1K sh shares · +80 new
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
13.68% of shares out · ▲ +7.0% MoM · 5.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
229 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $16 Now $78 · 85% Range high $88
vs 200-day avg +112% vs 50-day avg +17%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Adjusted EBITDA non-GAAP $25M Q2 2026 —
GAAP → non-GAAP reconciliation
GAAP Non-GAAP net income 19.99M
-1.74M Interest income
+3.83M Income tax expense (income)
+2.29M Depreciation expense
+440K Other expense (income), net
= Adjusted EBITDA 24.8M
Adjusted EBITDA margin non-GAAP 19% Three Months Ended June 30, 2026 —
Average revenue per test $1,720 Q2 2026 —
Free cash flow (non-GAAP) non-GAAP 28.75M Three Months Ended June 30, 2026 —
GAAP → non-GAAP reconciliation
GAAP Net cash provided by operating activities (GAAP) 30.61M
-1.86M Capital expenditures (GAAP)
= Free cash flow (non-GAAP) 28.75M
Non-GAAP basic net income per share non-GAAP $0.39 Three Months Ended June 30, 2026 —
Non-GAAP diluted net income per share non-GAAP $0.37 Three Months Ended June 30, 2026 —
Non-GAAP gross margin % non-GAAP 74% Three Months Ended June 30, 2026 —
Non-GAAP gross profit non-GAAP 97.97M Three Months Ended June 30, 2026 —
GAAP → non-GAAP reconciliation
GAAP GAAP gross profit 96.98M
+321K Stock-based compensation expense
+0K Restructuring costs
+311K Business development and portfolio optimization expense*
+355K Acquisition related-amortization of purchased intangibles
= Non-GAAP gross profit 97.97M
Non-GAAP net income non-GAAP 19.99M Three Months Ended June 30, 2026 —
GAAP → non-GAAP reconciliation
GAAP GAAP net income (loss) 110.64M
-112.97M Gain on sale of lab products business
+10.65M Stock-based compensation expense
+11.08M Business development and portfolio optimization expense*
+529K Acquisition related-amortization of purchased intangibles
+0K Acquisition related fees and expenses
+0K Change in estimated fair value of contingent consideration
+54K Tax effect related to amortization of purchased intangibles
+0K Transformational initiative costs
+0K Restructuring costs
+0K Litigation settlement expense
= Non-GAAP net income 19.99M
Testing services volume 58,000 Q2 2026 —
Total Non-GAAP operating expenses non-GAAP 75.45M Three Months Ended June 30, 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Diagnostics & Research — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
CDNA
CareDx, Inc.
this stock
$4.09B +313.4% +18.9% 32.6 13.7%
TMO
Thermo Fisher Scientific Inc.
 $259.44B +20.8% +14.5% 36.9 1.3%
DHR
Danaher Corp
 $163.94B +1.8% +8.5% 38.1 1.2%
IDXX
Idexx Laboratories Inc
 $55.48B +4.1% +10.4% 47.5 3.0%
A
Agilent Technologies, Inc.
 $49.04B +27.8% +6.4% 34.2 1.7%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
295
% held
101.9%
Reported
240 of 229
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
264
View
Short & Settlement
Short Interest Rising
Shares short
7.2M
Days to cover
5.3d
Change
+472.0K sh
View
Short Volume
Short vol %
42%
As of
Nov 13, 2026
Short Total
View
Fails to Deliver
FTD shares
9.6K
Value
$591.1K
As of
Sep 25, 2026
View
Off-Exchange
Off-exchange %
48.5%
Week of
Oct 5, 2026
Off-exch Lit
View
Smart Money
Congressional Trades Sell
Member
Daniel Goldman
Amount
$1.0K–$15.0K
Traded
Mar 6, 2023
View
Financials
Financials
Revenue (FY)
$379.8M
Net income (FY)
$-21.4M
EPS diluted
$-0.40
View
Buybacks
Authorized
$100.0M
Remaining
$0
Spent Remaining
View
Filings
SEC Filings
Latest
10-Q
Filed
Oct 29, 2026
This year
21

CareDx reported $139 million revenue and $19 million net income for the three months ended September 30, 2026. It sold its lab products business to Eurobio for $171.7 million and acquired Naveris for $203.3 million.

View
Proposed Sales
Value
$1.1M
Shares
13.8K
Filed
Nov 12, 2026
View
Earnings & Events
Webcasts
Last webcast
Oct 29, 2026
View
Investor Relations
Latest news
CareDx Announces Inducement Grant…
Published
Nov 6, 2026
View

Performance

5D 20D 120D MTD YTD
CDNA -0.9% +21.7% +261.6% -10.9% +313.4%
SPY +2.6% -1.2% +0.5% -0.2% +10.6%
vs SPY -3.5% +22.9% +261.1% -10.7% +302.8%

Capital returns

Buyback program · as of Sep 30, 2026
Authorized
$100.00M
Spent (derived)
$100.00M
Remaining
$0
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1217234 CUSIP 14167L103 13F (30d) 233 filings 213 filers Visit website Investor relations